Financial
FY2025 revenue $311.1m (+1.5%); operating margin -51.7%; net loss $178.0m.
Cash $95.7m; debt $153.3m.
Health Catalyst
HQ United States · North America
Directory listing. Financial health and risk summaries come from public sources only (see below); products have not been catalogued yet. Source: HSH editorial list from public company information, November 2026 — awaiting verification.
At a glance
Financial health
Band: Weak
Customer rating
No reviews yet
Financial health
Band: WeakListed: HCAT
FY2025 revenue $311.1m (+1.5%); operating margin -51.7%; net loss $178.0m.
Cash $95.7m; debt $153.3m.
Source: official results release · Year ended 2025-12-31 · Band from the latest full-year operating margin in official results: 10% or more Strong, 0–10% Fair, below 0 Weak. Where operating profit is not published, the stated alternative margin is used. Not assessed means no usable public figures.
| Year | Revenue | Growth | Operating profit | Net income | Covers |
|---|---|---|---|---|---|
| FY2025 | US$311.1m | +1.5% | -US$160.9m | -US$178m | Health Catalyst |
Products & services
Products not yet catalogued.
Risk summary
Full risk page with sources →Researched 8 Nov 2026
Adverse media
Aug 2025: Health Catalyst said long-time CEO Dan Burton would step down; Benjamin Albert is now CEO. Jul 2026: it sold its Vitalware business to Med-Metrix for $147m and used the proceeds to repay about $160m of debt.
Cyber & information governance
No data breaches, cyber incidents or regulator action involving Health Catalyst found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Healthcare data and analytics software supplier; no regulatory or clinical safety actions found in the last 24 months.
Contract performance
No notable contract disputes, terminations or troubled implementations involving Health Catalyst found in HSH's search of the last 24 months.
Competitors
No competitors linked yet.